Research Report: Overcoming the Final Frontier: A Comprehensive Analysis of Genetic and Immunosuppressive Strategies in the First Successful Pig-to-Human Lung Xenotransplantation

Executive Summary

This report provides a comprehensive synthesis of research into the first successful pig-to-human lung xenotransplantation, a landmark procedure conducted in 2024. The research query focused on the specific genetic modifications and immunosuppressive protocols that enabled a genetically engineered porcine lung to function for nine days (216 hours) in a brain-dead human recipient, and the implications of this outcome for long-term survival compared to heart and kidney xenografts.

The procedure's success in overcoming immediate, catastrophic rejection was built on a dual-pronged strategy. The donor pig underwent six critical genetic modifications: a "triple-knockout" of genes (GGTA1, B4GALNT2, CMAH) responsible for synthesizing hyperacute rejection-inducing xenoantigens, and a "triple-knock-in" of human genes (CD46, CD55, TBM) to provide active protection against the human complement and coagulation systems. This genetic foundation was coupled with a maximalist, multi-drug immunosuppressive protocol targeting nearly every major pathway of immune rejection. The regimen included agents for T-cell depletion (ATG), T-cell activation inhibition (Basiliximab, Tacrolimus, Belatacept), B-cell depletion (Rituximab), complement blockade (Eculizumab), and cytokine signaling inhibition (Tofacitinib), among others.

This combined strategy successfully averted hyperacute rejection (HAR), a historically insurmountable barrier in lung xenotransplantation, allowing the organ to perform gas exchange. However, the experiment also revealed the next formidable set of challenges. Within 24 hours, the xenograft developed severe edema resembling primary graft dysfunction (PGD), indicating a profound physiological vulnerability to ischemia-reperfusion injury. Furthermore, by postoperative day three, evidence of antibody-mediated rejection (AMR) emerged, suggesting that the genetic and pharmacological shields were incomplete. A critical analysis revealed that the immunosuppressive protocol notably lacked agents targeting the CD40-CD40L costimulatory pathway, a crucial checkpoint for antibody production, which likely contributed to the breakthrough AMR.

The nine-day survival of the lung xenograft, while a monumental scientific achievement, is significantly shorter than the multi-month survival times achieved in recent pig-to-human heart and kidney xenografts. This disparity underscores the unique and profound challenges presented by the lung, often termed the "Mount Everest" of xenotransplantation. Its direct exposure to the external environment, immense vascular surface area, inherent physiological fragility, and complex resident immune system create a higher-risk scenario for both immunological rejection and non-immunological injury.

In conclusion, this landmark case has shifted the paradigm for lung xenotransplantation from a question of 'if' to 'how'. It establishes a new baseline for the required genetic modifications and demonstrates that HAR is a solvable problem. However, it simultaneously proves that long-term survival will require a far more sophisticated approach than for other organs. Future success is contingent upon developing more advanced genetic platforms to control inflammation and innate immunity, refining immunosuppressive protocols to include mandatory CD40-CD40L blockade, and creating novel organ preservation and management strategies specifically designed to mitigate the lung's exquisite sensitivity to physiological injury.

1. Introduction

End-stage lung disease remains a leading cause of mortality worldwide, with lung transplantation being the only definitive treatment for many patients. However, the clinical application of this life-saving procedure is severely constrained by a critical shortage of suitable donor organs. For decades, xenotransplantation—the transplantation of organs between different species—has been pursued as a potential solution to this crisis. The pig has emerged as the most promising donor species due to its anatomical and physiological similarities to humans. Yet, the field has been historically plagued by formidable immunological barriers, most notably hyperacute rejection (HAR), an immediate and catastrophic immune response that destroys the xenograft within minutes to hours.

Recent advancements in genetic engineering, particularly the advent of CRISPR-Cas9 technology, and the development of novel immunosuppressive agents have reignited the potential of xenotransplantation. Landmark procedures involving the transplantation of genetically modified pig hearts and kidneys into human recipients in recent years have demonstrated survival for up to two months, marking a new era of clinical possibility. Within this context, the lung has long been considered the final and most difficult frontier. Its unique biological properties—including its vast vascular interface with the recipient's blood, its direct exposure to the external environment, and its profound sensitivity to physiological injury—present a cascade of challenges that exceed those of other solid organs.

In 2024, a team at Guangzhou Medical University First Affiliated Hospital, led by Dr. Jianxing He, conducted the world's first pig-to-human lung xenotransplantation in a brain-dead recipient model. The organ, sourced from a pig with six genetic modifications, remained viable and functional for nine days. This report provides a definitive synthesis of the available research on this groundbreaking procedure. It deconstructs the specific genetic and pharmacological strategies that enabled this success, analyzes the complex clinical outcomes, and contextualizes these findings within the broader landscape of xenotransplantation. By comparing the challenges encountered in this lung xenograft with those of previous heart and kidney xenografts, this report aims to illuminate the unique hurdles that must be overcome and to define a roadmap for achieving long-term recipient survival with this life-saving technology.

2. Key Findings

The synthesis of available data reveals a multi-faceted approach that, while successful in overcoming the initial immunological barriers, also unmasked a series of profound secondary challenges unique to the lung.

2.1 The Landmark Procedure: A Nine-Day Proof of Concept

The experiment, reported in Nature Medicine in August 2025, involved the transplantation of a single lung from a genetically modified Bama Xiang pig into a 39-year-old brain-dead male recipient. The procedure established a critical proof-of-concept by demonstrating that a porcine lung could be surgically implanted and maintain physiological function, including gas exchange (oxygenation of blood and clearance of carbon dioxide), within a human host for an unprecedented duration of 216 hours (nine days). The brain-dead recipient model provided a crucial ethical and scientific platform to study the organ's function and the host's immune response in detail without risk to a living patient. The experiment was terminated after nine days, having achieved its primary scientific objectives.

2.2 A Foundational Genetic Platform: The Six-Gene Modification Strategy

The cornerstone of the experiment's success in preventing immediate rejection was the advanced genetic engineering of the donor pig. The strategy involved six precise edits using CRISPR-Cas9 technology, creating a "3-knockout, 3-knock-in" platform designed to dismantle the primary molecular triggers of rejection and equip the organ with its own protective mechanisms.

• Three Gene Knockouts (Immunological Shield): The primary goal was to remove the main carbohydrate xenoantigens from the surface of porcine cells, rendering the organ less "foreign" to the human immune system.

  • GGTA1 (alpha-1,3-galactosyltransferase): Deletion of this gene prevents the synthesis of the α-Gal epitope, the most potent xenoantigen and the principal target for pre-existing human antibodies that trigger HAR.
  • B4GALNT2 (beta-1,4-N-acetylgalactosaminyltransferase 2): Knockout of this gene eliminates the SDa antigen, another major non-Gal carbohydrate target for human antibodies.
  • CMAH (cytidine monophosphate-N-acetylneuraminic acid hydroxylase): Deletion of this gene prevents the formation of the Neu5Gc antigen, a third key xenoantigen.

• Three Gene Knock-ins (Physiological Bridge): The secondary goal was to "humanize" the pig endothelium by inserting human genes that regulate key physiological pathways incompatible between the two species.

  • CD46 (Human Membrane Cofactor Protein) & CD55 (Human Decay-Accelerating Factor): Insertion of these two human complement-regulatory genes provides the porcine cells with the ability to deactivate the human complement cascade at their surface, shielding the graft from this powerful arm of the innate immune system.
  • TBM (Human Thrombomodulin): Introduction of this human anticoagulant gene helps to prevent thrombotic microangiopathy (TMA)—the formation of widespread micro-clots—by regulating the human coagulation cascade at the graft-host interface.

Table 1: Summary of the Six Genetic Modifications

Gene Edit Type	Gene Target	Function of Edit	Rationale
Knockout	GGTA1	Eliminates α-Gal xenoantigen	Prevents Hyperacute Rejection (HAR)
Knockout	B4GALNT2	Eliminates SDa xenoantigen	Reduces humoral rejection triggers
Knockout	CMAH	Eliminates Neu5Gc xenoantigen	Reduces humoral rejection triggers
Knock-in	hCD46	Expresses human complement regulator	Protects graft from human complement attack
Knock-in	hCD55	Expresses human complement regulator	Protects graft from human complement attack
Knock-in	hTBM	Expresses human anticoagulant protein	Prevents thrombotic microangiopathy (TMA)

2.3 A Maximalist Immunosuppressive Shield: The Multi-Drug Protocol

To complement the genetic modifications, the recipient was treated with an intensive and comprehensive immunosuppressive regimen designed to neutralize multiple arms of the immune system simultaneously. This "shock and awe" pharmacological strategy was dynamic and adjusted based on clinical observations. The protocol included:

• Induction Therapy: Rabbit anti-thymocyte globulin (rATG) for profound T-cell depletion and Basiliximab to block the IL-2 receptor on activated T-cells, preventing their proliferation.
• Humoral and Complement Blockade: Rituximab, an anti-CD20 antibody, was used to deplete B-cells, the precursors of antibody-producing plasma cells. Eculizumab, a C5 inhibitor, was administered to block the terminal complement pathway, providing a crucial backstop against complement-mediated damage.
• Costimulation Blockade: Belatacept was included to inhibit the T-cell costimulatory signals required for full activation.
• Cytokine Signaling Inhibition: Tofacitinib, a Janus kinase (JAK) inhibitor, was used to block key cytokine signaling pathways involved in coordinating the immune response.
• Maintenance Therapy: A standard combination of Tacrolimus (a calcineurin inhibitor) and Mycophenolate Mofetil (MMF, an anti-proliferative agent) was used to maintain a state of T-cell suppression.
• Anti-Inflammatory Therapy: Tapering corticosteroids were used for their broad-spectrum anti-inflammatory effects.

2.4 A Dual Outcome: Averting HAR While Unmasking New Hurdles

The combined genetic and pharmacological strategy yielded a mixed but highly informative set of clinical outcomes.

• Primary Success: The protocol was unequivocally successful in preventing hyperacute rejection. The lung did not undergo the immediate, catastrophic destruction that has defined past xenotransplantation attempts, proving the efficacy of the foundational strategy.
• Emergent Physiological Challenge: A major complication arose within the first 24 hours: the development of severe edema within the xenograft. This condition, resembling primary graft dysfunction (PGD), points to a severe non-immunological injury, likely related to ischemia-reperfusion, and highlights the lung's extreme physiological fragility.
• Persistent Immunological Challenge: Despite the heavy immunosuppression and B-cell depletion, signs of antibody-mediated rejection (AMR) were detected on postoperative days three and six. This demonstrates that the human immune system can still mount a delayed but potent humoral response against the remaining porcine antigens. The protocol's notable omission of agents targeting the CD40-CD40L costimulatory pathway is a likely contributor to this breakthrough rejection.

2.5 Comparative Xenograft Survival: Establishing the Lung as the Most Formidable Challenge

The nine-day survival of the lung xenograft, while groundbreaking, is significantly shorter than survival times achieved in other recent pig-to-human xenotransplants, starkly illustrating the organ-specific difficulties.

• Pig Kidney Xenografts: Have demonstrated the longest survival, functioning for up to 61 days in a brain-dead model and for over two months in a living recipient, who became dialysis-free.
• Pig Heart Xenografts: Have sustained life in two different living recipients for approximately 60 days each.
• Pig Lung Xenograft: The nine-day survival highlights a significant gap. This disparity is attributed to the lung's unique biological characteristics that make it the "Mount Everest" of xenotransplantation: its constant exposure to the external environment, its vast and delicate vascular network, its high susceptibility to inflammatory injury, and its complex resident immune system.

3. Detailed Analysis

A deeper analysis of the findings reveals the intricate interplay between the engineered organ and the host environment, providing critical insights into the mechanisms of both success and failure.

3.1 The Synergy of Genetic and Pharmacological Intervention

The nine-day viability was not the result of a single breakthrough but of a powerful synergy between two complementary strategies. The genetic modifications served to lower the organ's intrinsic immunogenicity, reducing the "foreignness" of the graft to a manageable level. This can be conceptualized as lowering the immunological "mountain" that the immunosuppressive drugs had to climb. The "triple-knockout" of xenoantigens effectively dismantled the primary targets for pre-existing antibodies, preventing the instantaneous HAR cascade. The "triple-knock-in" of human regulatory proteins provided an active, localized defense system against complement and coagulation dysregulation.

This genetic groundwork allowed the multi-drug immunosuppressive regimen to be effective. Without the genetic edits, even this maximalist protocol would have been overwhelmed by HAR. Conversely, the genetic edits alone are insufficient, as demonstrated by the eventual onset of AMR. The drugs were essential for suppressing the adaptive immune response to the remaining minor porcine antigens and controlling the inflammatory sequelae of the surgery. The key takeaway is that neither strategy is sufficient in isolation; future success in xenotransplantation is fundamentally dependent on optimizing this synergistic relationship.

3.2 Deconstructing the Genetic Architecture: Beyond α-Gal

While the knockout of GGTA1 has been the cornerstone of xenotransplantation for over a decade, this experiment's success underscores the importance of a multi-antigen knockout strategy. By also eliminating Neu5Gc and SDa antigens, the platform addressed the phenomenon of "antibody shifting," where the immune system, deprived of its primary α-Gal target, mounts a robust response against secondary carbohydrate antigens. This "triple-knockout" (TKO) model represents a new and necessary baseline for mitigating humoral rejection.

Similarly, the knock-in strategy addressed critical physiological incompatibilities. The expression of human complement regulators hCD46 and hCD55 is vital because even in the absence of antibody binding, the alternative complement pathway can be spontaneously activated on foreign surfaces. Porcine complement regulators are inefficient at controlling the human cascade, making this "humanization" essential to prevent slow-burn endothelial damage. The inclusion of human thrombomodulin (hTBM) was equally critical. Incompatibilities in the coagulation cascade can turn the vast endothelial surface of the lung into a pro-thrombotic minefield, leading to TMA. hTBM helps maintain a non-thrombogenic surface, a factor of paramount importance in such a highly vascularized organ.

3.3 Anatomy of an Immunosuppressive Arsenal and a Critical Omission

The immunosuppressive protocol was a masterclass in multi-pathway blockade, reflecting a deep understanding of rejection mechanisms. The induction with rATG and Basiliximab aimed to achieve a state of profound T-cell lymphopenia from the outset. The inclusion of Eculizumab provided a powerful safety net against complement-mediated injury. The maintenance regimen of Tacrolimus and MMF is a standard of care in allotransplantation, while the addition of newer agents like the JAK inhibitor Tofacitinib and the costimulation blocker Belatacept represents a modern, multi-pronged approach.

However, the most analytically significant aspect of the protocol is what was absent: a direct antagonist of the CD40-CD40L (also known as CD154) costimulatory pathway. This pathway is the central checkpoint for T-cell "help" to B-cells, a process essential for affinity maturation, class switching, and the generation of a high-titer, long-lived antibody response. Preclinical studies in non-human primates have consistently shown that CD40-CD40L blockade is arguably the single most effective strategy for preventing AMR and inducing long-term graft tolerance.

The fact that AMR emerged as a key mechanism of graft injury by day three, despite the use of the B-cell depleting agent Rituximab, strongly implicates the unblocked CD40-CD40L pathway. This suggests that a residual or newly developed B-cell population was activated, leading to the production of donor-specific antibodies. This clinical finding elevates the importance of CD40-CD40L blockade from a promising preclinical strategy to a clinical imperative for future xenotransplantation trials.

3.4 The Pathophysiology of Early Graft Failure: Beyond Rejection

Perhaps the most crucial lesson from this experiment is that immunological rejection is not the only—or even the first—major barrier to lung xenograft survival. The rapid onset of severe, PGD-like edema within 24 hours points to a profound physiological incompatibility and a hyper-acute inflammatory response driven by non-immunological factors.

This is likely a severe manifestation of ischemia-reperfusion injury (IRI). The lung is uniquely susceptible to IRI due to its delicate alveolar-capillary membrane and massive vascular bed. The process of organ procurement, preservation, and reperfusion with human blood likely triggers a massive inflammatory cascade, leading to endothelial damage, capillary leakage, and fluid accumulation in the alveolar spaces, severely impairing gas exchange. This initial physiological insult creates a pro-inflammatory microenvironment within the graft that can attract immune cells and amplify subsequent immunological rejection processes like AMR. This finding demonstrates that for lungs, success will depend as much on advances in organ preservation and perioperative anti-inflammatory management as it does on immunosuppression.

4. Discussion

The successful nine-day functioning of a pig lung in a human body is a landmark scientific achievement that fundamentally alters the landscape of xenotransplantation. It serves as a vital proof-of-concept, yet it simultaneously illuminates the immense, organ-specific challenges that define the path forward.

4.1 The "Mount Everest" of Xenotransplantation: Why the Lung Is Different

This study empirically validates the long-held view of the lung as the most challenging organ for xenotransplantation. The reasons are multifaceted and distinguish it clearly from the heart and kidney.

1. The Environmental Interface: The lung is the only internal organ in direct contact with the external environment. Every breath introduces a host of potential pathogens, allergens, and pollutants. This necessitates a highly active resident immune system (e.g., alveolar macrophages) and creates a state of continuous immune surveillance and inflammation that is absent in sterile organs like the heart and kidney. Suppressing rejection without crippling this essential defense mechanism is a central and unresolved dilemma.
2. Physiological Fragility: As evidenced by the rapid onset of edema, the lung's delicate structure is exquisitely sensitive to injury. Its primary function—gas exchange across a membrane only one cell thick—can be catastrophically compromised by fluid shifts and inflammation that might be better tolerated in other organs.
3. Vast Immunological Target: The lung's alveolar-capillary network has a surface area comparable to a tennis court. This presents an enormous target for circulating antibodies, complement proteins, and immune cells, amplifying the potential for rejection-mediated damage.
4. Complex Resident Immunity: The lung contains a dense population of tissue-resident immune cells. Managing the interaction between these cells and the recipient's systemic immune response adds a layer of complexity not present in other solid organ xenografts.

These factors combine to create a uniquely hostile environment for a xenograft. While kidney and heart xenografts must contend with systemic rejection, the lung must survive a dual assault from both systemic immunity and a localized, hyper-inflammatory, and environmentally-exposed milieu.

4.2 Lessons Learned: Averting HAR Reveals the Next Immunological Frontier

By successfully solving the problem of hyperacute rejection, this experiment has allowed the scientific community to see the next set of immunological barriers with unprecedented clarity. The emergence of AMR by day three is a critical finding. It confirms that even with a triple-knockout of major xenoantigens, the human immune system retains the ability to recognize and attack the pig organ. This underscores the need for more comprehensive strategies to control humoral immunity. The failure to include CD40-CD40L blockade, a therapy that has shown immense promise in primate models, stands out as the most significant and actionable lesson from the immunosuppressive protocol. Future trials will almost certainly incorporate this pathway blockade as a cornerstone of their regimen.

4.3 The Path to Long-Term Survival: A Roadmap for Future Research

This nine-day success provides not a final answer, but a detailed blueprint of the work that remains. Achieving long-term survival for lung xenograft recipients will require a multi-pronged evolution of current strategies.

• Next-Generation Genetic Modifications: The six-gene platform is a new baseline. Future donor pigs will likely require a more sophisticated suite of edits. This may include the insertion of human genes that actively suppress inflammation (e.g., hA20, hHO-1), evade innate immune cells like macrophages and NK cells (e.g., hCD47, a "don't eat me" signal), and provide even more robust regulation of the coagulation cascade (e.g., hEPCR, hTFPI).
• Refined Immunosuppressive Protocols: The clinical imperative is to incorporate CD40-CD40L inhibitors (e.g., Tegoprubart). The goal will be to create a more targeted immune blockade that can specifically prevent AMR without the need for the current, globally-suppressive "shock and awe" approach, which carries unacceptable long-term risks of infection and toxicity.
• Lung-Specific Physiological Management: The severe PGD-like edema highlights a critical need for innovation outside of immunology. Developing novel organ preservation techniques (e.g., normothermic machine perfusion) and aggressive perioperative anti-inflammatory therapies will be essential to mitigate IRI and give the xenograft the best possible start.

4.4 Contextualizing Success: Short-Term Viability vs. Long-Term Clinical Reality

It is essential to temper the excitement surrounding this achievement with a realistic perspective. A nine-day success in a brain-dead model is a monumental scientific step, but it is far from a clinical solution. It does not provide data on the challenges of chronic rejection, a slow, insidious process of fibrosis and vascular damage that can lead to graft failure over months or years. Furthermore, the sheer intensity of the immunosuppression required raises profound concerns about long-term recipient health, particularly the risk of life-threatening opportunistic infections in an organ constantly exposed to pathogens. The road to making pig lungs a routine, life-saving therapy is still long and complex, and will require solving these subsequent, more nuanced challenges.

5. Conclusions

The first successful pig-to-human lung xenotransplantation represents a watershed moment in medical science. The nine-day viability of the organ, achieved through a synergistic combination of a six-gene modified donor pig and a maximalist immunosuppressive regimen, has definitively proven that the primary barrier of hyperacute rejection in the lung is surmountable. This accomplishment shifts the focus of research from preventing immediate catastrophe to managing the complex, organ-specific challenges of the sub-acute and chronic phases.

The key takeaways are threefold. First, the "triple-knockout, triple-knock-in" genetic platform provides a viable and necessary foundation for future attempts. Second, the emergence of severe edema and antibody-mediated rejection reveals the next critical frontiers: mitigating profound physiological injury (PGD/IRI) and achieving more complete control of humoral immunity. The omission of CD40-CD40L costimulatory blockade stands as a critical lesson, and its inclusion is now an imperative for subsequent trials.

Finally, this study empirically confirms that the lung is the most formidable challenge in xenotransplantation, requiring a more sophisticated and multi-faceted approach than that for either the heart or kidney. The path to long-term survival for lung recipients will be significantly steeper, demanding parallel advancements in genetic engineering, targeted immunomodulation, and lung-specific physiological management. While this nine-day success does not signal the immediate clinical availability of xenogeneic lungs, it provides the crucial proof-of-concept and the invaluable scientific roadmap needed to navigate the complex journey ahead toward solving the critical shortage of organs for patients with end-stage lung disease.

References

Total unique sources: 126

ID	Source	ID	Source	ID	Source
[1]	geneonline.com	[2]	medmultilingua.com	[3]	futuroprossimo.it
[4]	evrimagaci.org	[5]	medium.com	[6]	sustainability-times.com
[7]	researchgate.net	[8]	nih.gov	[9]	youtube.com
[10]	the-innovation.org	[11]	nih.gov	[12]	duke.edu
[13]	nih.gov	[14]	eujtransplantation.com	[15]	nih.gov
[16]	nih.gov	[17]	twistedsifter.com	[18]	quora.com
[19]	theguardian.com	[20]	evrimagaci.org	[21]	chinadailyhk.com
[22]	understandinganimalresearch.org.uk	[23]	sustainability-times.com	[24]	medmultilingua.com
[25]	nih.gov	[26]	frontierspartnerships.org	[27]	nih.gov
[28]	interhospi.com	[29]	nih.gov	[30]	researchgate.net
[31]	medmultilingua.com	[32]	futuroprossimo.it	[33]	frontiersin.org
[34]	nih.gov	[35]	dntb.gov.ua	[36]	frontiersin.org
[37]	nih.gov	[38]	nih.gov	[39]	nih.gov
[40]	frontiersin.org	[41]	researchgate.net	[42]	eujtransplantation.com
[43]	eujtransplantation.com	[44]	nih.gov	[45]	physiology.org
[46]	physiology.org	[47]	jcvi.org	[48]	nih.gov
[49]	medmultilingua.com	[50]	medium.com	[51]	evrimagaci.org
[52]	sciencemediacentre.org	[53]	antibodysystem.com	[54]	frontierspartnerships.org
[55]	nih.gov	[56]	geneonline.com	[57]	researchgate.net
[58]	physiology.org	[59]	nso-journal.org	[60]	researchgate.net
[61]	futuroprossimo.it	[62]	nih.gov	[63]	medmultilingua.com
[64]	medium.com	[65]	researchgate.net	[66]	nih.gov
[67]	nih.gov	[68]	interhospi.com	[69]	duke.edu
[70]	bioworld.com	[71]	researchgate.net	[72]	sciencemediacentre.org
[73]	sciencemediacentre.es	[74]	theguardian.com	[75]	nih.gov
[76]	interhospi.com	[77]	sciencenews.org	[78]	understandinganimalresearch.org.uk
[79]	bioworld.com	[80]	theguardian.com	[81]	chosun.com
[82]	ssbcrack.com	[83]	hcplive.com	[84]	eujtransplantation.com
[85]	researchgate.net	[86]	nih.gov	[87]	nih.gov
[88]	ishlt.org	[89]	nih.gov	[90]	nih.gov
[91]	nyulangone.org	[92]	physiology.org	[93]	nyulangone.org
[94]	medpath.com	[95]	nih.gov	[96]	sciencedaily.com
[97]	nih.gov	[98]	physiology.org	[99]	researchgate.net
[100]	nih.gov	[101]	nih.gov	[102]	sciencealert.com
[103]	nationalgeographic.com	[104]	sciencenews.org	[105]	nih.gov
[106]	researchgate.net	[107]	youtube.com	[108]	nih.gov
[109]	sciencemediacentre.org	[110]	ctsnet.org	[111]	theguardian.com
[112]	eujtransplantation.com	[113]	nih.gov	[114]	geneonline.com
[115]	nationalgeographic.com	[116]	sciencenews.org	[117]	theguardian.com
[118]	healthandme.com	[119]	ssbcrack.com	[120]	independent.co.uk
[121]	kompas.id	[122]	medmultilingua.com	[123]	interhospi.com
[124]	rebiogroup.com	[125]	youtube.com	[126]	nih.gov